Market research
PAR.AU Paradigm Biopharmaceuticals Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 1.08
- Dividend yield
- Not available
- Beta
- -0.01
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000PAR5
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 1.08
- Dividend yield
- Not available
- Beta
- -0.01
About
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PAR.AU discussion.
5 years, 5 months ago
Paradigm Biopharmaceuticals Limited is currently in a long term downtrend where the price is trading 19.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Paradigm Biopharmaceuticals Limited's total revenue sank by 69.2% to $254K since the same quarter in the previous year.
Its net income has dropped by 306.2% to $-21M since the same quarter in the previous year.
Finally, its free cash flow fell by 217.1% to $-10M since the same quarter in the previous year.
Based on the above factors, Paradigm Biopharmaceuticals Limited gets an overall score of 1/5.